Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Medivir AB's Debt-to-Equity or its related term are showing as below:
LTS:0GP7'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.08 Max: 0.24
Current: 0.03
During the past 13 years, the highest Debt-to-Equity Ratio of Medivir AB was 0.24. The lowest was 0.05. And the median was 0.08.
LTS:0GP7's Debt-to-Equity is ranked better than 81.03% of 954
companies
in the Biotechnology industry
Industry Median: 0.16
vs LTS:0GP7: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Medivir AB Debt-to-Equity Related Terms
Medivir AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Medivir AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0GP7 vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Medivir AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medivir AB Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medivir AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Medivir AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medivir AB (LTS:0GP7) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medivir AB and its competitors. Over the past decade, Medivir AB's Debt-to-Equity has ranged from 0.05 to 0.24. According to the industry distribution chart, Medivir AB ranks #181 out of 954 companies in the Biotechnology industry, placing it in the top 19%.
Is Medivir AB's Debt-to-Equity too high?
Medivir AB's current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.24. Based on the distribution chart, Medivir AB ranks #181 out of 954 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Medivir AB has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medivir AB ranks #181 out of 954 companies for Debt-to-Equity. This places Medivir AB in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Historically, Medivir AB's own Debt-to-Equity has ranged from 0.05 to 0.24 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medivir AB and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medivir AB's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (LTS:0GP7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.01, compared to a current price of kr1.90 — trading 88.2% above its estimated fair value. The current Debt-to-Equity is 0.00. Medivir AB's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Medivir AB (LTS:0GP7), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medivir AB (LTS:0GP7) Overvalued in 2026?
Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued.
The current stock price of kr1.90 is trading 88.2% above its estimated GF Value™ of kr1.01.
GuruFocus considers Medivir AB to be Significantly Overvalued.
Key valuation signals for LTS:0GP7:
Debt-to-Equity: 0.00
GF Value™: kr1.01 vs. price of kr1.90 (88.2% above fair value)
No single metric tells the full story. See the LTS:0GP7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
44GF Score
Get the complete analysis for LTS:0GP7
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0GP7 has been successfully added to your 
